Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan


Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article


Management of pediatric rheumatologic diseases has evolved considerably. Development of biologics is a major factor contributing to this. Collaborative efforts are a major factor in the conduct of multiple trials. These developments raise the hope of overall improved outcomes and better long-term functional outcomes in children suffering from rheumatologic diseases.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: